Sally Hunter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sally Hunter has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Carol Brayne
Cambridge Public Health, University of Cambridge School of Clinical Medicine, Cambridge, UK
22 shared publications - Fiona Elaine Matthews
Institute for Clinical and Applied Research, University of Hull, Hull HU6 7RX, UK
7 shared publications - Blossom Christa Maree Stephan
Curtin-Chulalongkorn Collaborative Centre for Nutrition and Food Research and Education, Curtin University, Perth, WA 6845, Australia
3 shared publications - Hannah Amy Dianne Keage
School of Psychology, College of Education, Behavioural and Social Sciences, Adelaide University , Adelaide, South Australia
3 shared publications - Suvi R. K. Hokkanen
IQVIA, London, UK
3 shared publications - Tom Dening
University of Nottingham
3 shared publications
Latest Publications
- Open Access
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (10) , 1-10
Key questions for the future of amyloid research in dementia: a framework for integrating complex datasets
Alzheimer’s disease research is moving into a new era, yet significant questions remain about its underlying biological mechanisms. In this article, we consider how the field might refine the transfer of evidence between research cohorts focused on rare, genetically defined familial forms of dementia, clinical trial cohorts, highly selective of relatively younger people, with single neuropathologies and few co-morbidities, and the overall picture of the dementia syndrome in the whole population. We examine four key areas in which the evidence base must be improved: i) how ‘disease’ definitions apply across these three groups, ii) the precise molecular identification of the protein at the heart of current Alzheimer’s research - amyloid beta protein, iii) the contributions of the full amyloid precursor protein proteolytic system and iv) how this complex proteolytic system relates to wider cellular systems. We describe how a cross-disciplinary approach based on the APP matrix framework, could allow a systematic investigation of new perspectives to inform translational research and precision medicine approaches. Addressing these gaps will give us the biological grounding needed to provide a sound underpinning to innovations in the field.
- 22 August 2025
- Published by Springer Nature in Molecular Psychiatry
- Vol. 30 (10) , 1-10
Open AccessKey questions for the future of amyloid research in dementia: a framework for integrating complex datasets
Alzheimer’s disease research is moving into a new era, yet significant questions remain about its underlying biological mechanisms. In this article, we consider how the field might refine the transfer of evidence between research cohorts focused on rare, genetically defined familial forms of dementia, clinical trial cohorts, highly selective of relatively younger people, with single neuropathologies and few co-morbidities, and the overall picture of the dementia syndrome in the whole population. We examine four key areas in which the evidence base must be improved: i) how ‘disease’ definitions apply across these three groups, ii) the precise molecular identification of the protein at the heart of current Alzheimer’s research - amyloid beta protein, iii) the contributions of the full amyloid precursor protein proteolytic system and iv) how this complex proteolytic system relates to wider cellular systems. We describe how a cross-disciplinary approach based on the APP matrix framework, could allow a systematic investigation of new perspectives to inform translational research and precision medicine approaches. Addressing these gaps will give us the biological grounding needed to provide a sound underpinning to innovations in the field.
- Open Access
- 1 January 2021
- Published by Elsevier in Aging Brain
- Vol. 1, 100008
Amyloid in the ageing brain: New frameworks and perspectives
- 1 January 2021
- Published by Elsevier in Aging Brain
- Vol. 1, 100008
Open AccessAmyloid in the ageing brain: New frameworks and perspectives
- Open Access
- 24 September 2018
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 48 (12) , e13025
Aβ and the dementia syndrome: Simple versus complex perspectives
Background: The amyloid cascade hypothesis (ACH) has dominated strategy in dementia research for decades despite evidence of its limitations including known heterogeneity of the dementia syndrome in the population and the narrow focus on a single molecule – the amyloid beta protein (Aβ) as causal for all Alzheimer‐type dementia. Other hypotheses relevant to Aβ are the presenilin (PS) hypothesis (PSH) relating to the involvement of PS in the generation of Aβ, and the amyloid precursor protein (APP) matrix approach (AMA), relating to the complex and dynamic breakdown of APP, from which Aβ derives.Materials and methods: In this article we explore perspectives relating to complex disorders occurring mainly in older populations through a detailed case study of the role of Aβ in AD.Results: Scrutiny of the evidence generated so far reveals and a lack of understanding of the wider APP proteolytic system and how narrow research into the dementia syndrome has been to date. Confounding factors add significant limitations to the understanding of the current evidence base.Conclusions: A better characterisation of the entire APP proteolytic system in the human brain is urgently required to place Aβ in its complex physiological context. From a molecular perspective, a combination of the alternative hypotheses, the PSH and the AMA may better describe the complexity of the APP proteolytic system leading to new therapeutic approaches. The reductionist approach is widespread throughout biomedical research and this example highlights how neglect of complexity can undermine investigations of complex disorders, particularly those arising in the oldest in our populations.
- 24 September 2018
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 48 (12) , e13025
Open AccessAβ and the dementia syndrome: Simple versus complex perspectives
Background: The amyloid cascade hypothesis (ACH) has dominated strategy in dementia research for decades despite evidence of its limitations including known heterogeneity of the dementia syndrome in the population and the narrow focus on a single molecule – the amyloid beta protein (Aβ) as causal for all Alzheimer‐type dementia. Other hypotheses relevant to Aβ are the presenilin (PS) hypothesis (PSH) relating to the involvement of PS in the generation of Aβ, and the amyloid precursor protein (APP) matrix approach (AMA), relating to the complex and dynamic breakdown of APP, from which Aβ derives.Materials and methods: In this article we explore perspectives relating to complex disorders occurring mainly in older populations through a detailed case study of the role of Aβ in AD.Results: Scrutiny of the evidence generated so far reveals and a lack of understanding of the wider APP proteolytic system and how narrow research into the dementia syndrome has been to date. Confounding factors add significant limitations to the understanding of the current evidence base.Conclusions: A better characterisation of the entire APP proteolytic system in the human brain is urgently required to place Aβ in its complex physiological context. From a molecular perspective, a combination of the alternative hypotheses, the PSH and the AMA may better describe the complexity of the APP proteolytic system leading to new therapeutic approaches. The reductionist approach is widespread throughout biomedical research and this example highlights how neglect of complexity can undermine investigations of complex disorders, particularly those arising in the oldest in our populations.
- 12 June 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 64 (s1) , S119-S143
Dementia Research: Populations, Progress, Problems, and Predictions
Alzheimer’s disease (AD) is a clinicopathologically defined syndrome leading to cognitive impairment. Following the recent failures of amyloid-based randomized controlled trials to change the course of AD, there are growing calls for a re-evaluation
- 12 June 2018
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 64 (s1) , S119-S143
Dementia Research: Populations, Progress, Problems, and Predictions
Alzheimer’s disease (AD) is a clinicopathologically defined syndrome leading to cognitive impairment. Following the recent failures of amyloid-based randomized controlled trials to change the course of AD, there are growing calls for a re-evaluation
- 7 November 2017
- Published by Springer Nature in Molecular Psychiatry
- Vol. 23 (1) , 81-93
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Many models of disease progression in Alzheimer's disease (AD) have been proposed to help guide experimental design and aid the interpretation of results. Models focussing on the genetic evidence include the amyloid cascade (ACH) and presenilin (PSH) hypotheses and the amyloid precursor protein (APP) matrix approach (AMA), of which the ACH has held a dominant position for over two decades. However, the ACH has never been fully accepted and has not yet delivered on its therapeutic promise. We review the ACH, PSH and AMA in relation to levels of APP proteolytic fragments reported from AD-associated mutations in APP. Different APP mutations have diverse effects on the levels of APP proteolytic fragments. This evidence is consistent with at least three disease pathways that can differ between familial and sporadic AD and two pathways associated with cerebral amyloid angiopathy. We cannot fully evaluate the ACH, PSH and AMA in relation to the effects of mutations in APP as the APP proteolytic system has not been investigated systematically. The confounding effects of sequence homology, complexity of competing cleavages and antibody cross reactivities all illustrate limitations in our understanding of the roles these fragments and the APP proteolytic system as a whole in normal aging and disease play. Current experimental design should be refined to generate clearer evidence, addressing both aging and complex disorders with standardised reporting formats. A more flexible theoretical framework capable of accommodating the complexity of the APP proteolytic system is required to integrate available evidence.
- 7 November 2017
- Published by Springer Nature in Molecular Psychiatry
- Vol. 23 (1) , 81-93
Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease
Many models of disease progression in Alzheimer's disease (AD) have been proposed to help guide experimental design and aid the interpretation of results. Models focussing on the genetic evidence include the amyloid cascade (ACH) and presenilin (PSH) hypotheses and the amyloid precursor protein (APP) matrix approach (AMA), of which the ACH has held a dominant position for over two decades. However, the ACH has never been fully accepted and has not yet delivered on its therapeutic promise. We review the ACH, PSH and AMA in relation to levels of APP proteolytic fragments reported from AD-associated mutations in APP. Different APP mutations have diverse effects on the levels of APP proteolytic fragments. This evidence is consistent with at least three disease pathways that can differ between familial and sporadic AD and two pathways associated with cerebral amyloid angiopathy. We cannot fully evaluate the ACH, PSH and AMA in relation to the effects of mutations in APP as the APP proteolytic system has not been investigated systematically. The confounding effects of sequence homology, complexity of competing cleavages and antibody cross reactivities all illustrate limitations in our understanding of the roles these fragments and the APP proteolytic system as a whole in normal aging and disease play. Current experimental design should be refined to generate clearer evidence, addressing both aging and complex disorders with standardised reporting formats. A more flexible theoretical framework capable of accommodating the complexity of the APP proteolytic system is required to integrate available evidence.
- Open Access
- 25 September 2017
- Published by Wiley in Brain Pathology
- Vol. 28 (4) , 548-559
Hippocampal sclerosis, hippocampal neuron loss patterns and TDP‐43 in the aged population
Hippocampal neuron loss is a common neuropathological feature in old age with various underlying etiologies. Hippocampal sclerosis of aging (HS‐Aging) is neuropathologically characterized by severe CA1 neuronal loss and frequent presence of transactive response DNA‐binding protein of 43 kDa (TDP‐43) aggregations. Its etiology is unclear and currently no standardized approaches to measure HS‐Aging exist. We developed a semi‐quantitative protocol, which captures various hippocampal neuron loss patterns, and compared their occurrence in the context of HS‐Aging, TDP‐43, vascular and tau pathology in 672 brains (TDP‐43 staining n = 642/672, 96%) donated for the population‐based Cambridge City over‐75s Cohort and the Cognitive Function and Ageing Study. HS‐Aging was first evaluated independently from the protocol using the most common criteria defined in literature, and then described in detail through examination of neuron loss patterns and associated pathologies. 34 (5%) cases were identified, with a maximum of five pyramidal neurons in each of over half CA1 fields‐of‐view (x200 magnification), no vascular damage, no neuron loss in CA2‐CA4, but consistent TDP‐43 neuronal solid inclusions and neurites. We also report focal CA1 neuron loss with vascular pathology to affect predominantly CA1 bordering CA2 (Fisher's exact, P = 0.009), whereas neuron loss in the subicular end of CA1 was associated with TDP‐43 inclusions (Fisher's exact, P < 0.001) and high Braak stage (Fisher's exact, P = 0.001). Hippocampal neuron loss in CA4‐CA2 was not associated with TDP‐43. We conclude that hippocampal neuron loss patterns are associated with different etiologies within CA1, and propose that these patterns can be used to form objective criteria for HS‐Aging diagnosis. Finally, based on our results we hypothesize that neuron loss leading to HS‐Aging starts from the subicular end of CA1 when it is associated with TDP‐43 pathology, and that this neurodegenerative process is likely to be significantly more common than “end‐stage” HS‐Aging only.
- 25 September 2017
- Published by Wiley in Brain Pathology
- Vol. 28 (4) , 548-559
Open AccessHippocampal sclerosis, hippocampal neuron loss patterns and TDP‐43 in the aged population
Hippocampal neuron loss is a common neuropathological feature in old age with various underlying etiologies. Hippocampal sclerosis of aging (HS‐Aging) is neuropathologically characterized by severe CA1 neuronal loss and frequent presence of transactive response DNA‐binding protein of 43 kDa (TDP‐43) aggregations. Its etiology is unclear and currently no standardized approaches to measure HS‐Aging exist. We developed a semi‐quantitative protocol, which captures various hippocampal neuron loss patterns, and compared their occurrence in the context of HS‐Aging, TDP‐43, vascular and tau pathology in 672 brains (TDP‐43 staining n = 642/672, 96%) donated for the population‐based Cambridge City over‐75s Cohort and the Cognitive Function and Ageing Study. HS‐Aging was first evaluated independently from the protocol using the most common criteria defined in literature, and then described in detail through examination of neuron loss patterns and associated pathologies. 34 (5%) cases were identified, with a maximum of five pyramidal neurons in each of over half CA1 fields‐of‐view (x200 magnification), no vascular damage, no neuron loss in CA2‐CA4, but consistent TDP‐43 neuronal solid inclusions and neurites. We also report focal CA1 neuron loss with vascular pathology to affect predominantly CA1 bordering CA2 (Fisher's exact, P = 0.009), whereas neuron loss in the subicular end of CA1 was associated with TDP‐43 inclusions (Fisher's exact, P < 0.001) and high Braak stage (Fisher's exact, P = 0.001). Hippocampal neuron loss in CA4‐CA2 was not associated with TDP‐43. We conclude that hippocampal neuron loss patterns are associated with different etiologies within CA1, and propose that these patterns can be used to form objective criteria for HS‐Aging diagnosis. Finally, based on our results we hypothesize that neuron loss leading to HS‐Aging starts from the subicular end of CA1 when it is associated with TDP‐43 pathology, and that this neurodegenerative process is likely to be significantly more common than “end‐stage” HS‐Aging only.
- 9 August 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 44 (3) , 286-297
Prevalence of transactive response DNA‐binding protein 43 (TDP‐43) proteinopathy in cognitively normal older adults: systematic review and meta‐analysis
Objective: To perform a systematic review and meta‐analysis on the prevalence of transactive response DNA‐binding protein 43 (TDP‐43) proteinopathy in cognitively normal older adults.Methods: We systematically reviewed and performed a meta‐analysis on the prevalence of TDP‐43 proteinopathy in older adults with normal cognition, evaluated by the Mini‐Mental State Examination or the Clinical Dementia Rating. We estimated the overall prevalence of TDP‐43 using random‐effect models, and stratified by age, sex, sample size, study quality, antibody used to assess TDP‐43 aggregates, analysed brain regions, Braak stage, Consortium to Establish a Registry for Alzheimer's Disease score, hippocampal sclerosis and geographic location.Results: A total of 505 articles were identified in the systematic review, and 7 were included in the meta‐analysis with 1196 cognitively normal older adults. We found an overall prevalence of TDP‐43 proteinopathy of 24%. Prevalence of TDP‐43 proteinopathy varied widely across geographic location (North America: 37%, Asia: 29%, Europe: 14%, and Latin America: 11%). Estimated prevalence of TDP‐43 proteinopathy also varied according to study quality (quality score >7: 22% vs. quality score vs. hyperphosphorylated: 24%) and presence of hippocampal sclerosis (without 24% vs. with hippocampal sclerosis: 48%). Other stratified analyses by age, sex, analysed brain regions, sample size and severity of AD neuropathology showed similar pooled TDP‐43 prevalence.Conclusions: Different methodology to access TDP‐43, and also differences in lifestyle and genetic factors across different populations could explain our results. Standardization of TDP‐43 measurement, and future studies about the impact of genetic and lifestyle characteristics on the development of neurodegenerative diseases are needed.
- 9 August 2017
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 44 (3) , 286-297
Prevalence of transactive response DNA‐binding protein 43 (TDP‐43) proteinopathy in cognitively normal older adults: systematic review and meta‐analysis
Objective: To perform a systematic review and meta‐analysis on the prevalence of transactive response DNA‐binding protein 43 (TDP‐43) proteinopathy in cognitively normal older adults.Methods: We systematically reviewed and performed a meta‐analysis on the prevalence of TDP‐43 proteinopathy in older adults with normal cognition, evaluated by the Mini‐Mental State Examination or the Clinical Dementia Rating. We estimated the overall prevalence of TDP‐43 using random‐effect models, and stratified by age, sex, sample size, study quality, antibody used to assess TDP‐43 aggregates, analysed brain regions, Braak stage, Consortium to Establish a Registry for Alzheimer's Disease score, hippocampal sclerosis and geographic location.Results: A total of 505 articles were identified in the systematic review, and 7 were included in the meta‐analysis with 1196 cognitively normal older adults. We found an overall prevalence of TDP‐43 proteinopathy of 24%. Prevalence of TDP‐43 proteinopathy varied widely across geographic location (North America: 37%, Asia: 29%, Europe: 14%, and Latin America: 11%). Estimated prevalence of TDP‐43 proteinopathy also varied according to study quality (quality score >7: 22% vs. quality score vs. hyperphosphorylated: 24%) and presence of hippocampal sclerosis (without 24% vs. with hippocampal sclerosis: 48%). Other stratified analyses by age, sex, analysed brain regions, sample size and severity of AD neuropathology showed similar pooled TDP‐43 prevalence.Conclusions: Different methodology to access TDP‐43, and also differences in lifestyle and genetic factors across different populations could explain our results. Standardization of TDP‐43 measurement, and future studies about the impact of genetic and lifestyle characteristics on the development of neurodegenerative diseases are needed.
- Open Access
- 8 March 2017
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 16 (1) , 8
Erratum to: Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
- 8 March 2017
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 16 (1) , 8
Open AccessErratum to: Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
- Open Access
- 26 January 2017
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 16 (1) , 1-8
Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
Alzheimer disease (AD) research has focussed mainly on the amyloid beta protein (Aβ). However, many Aβ-and P3-type peptides derived from the amyloid precursor protein (APP) and peptides thought to derive from Aβ catabolism share sequence homology. Additionally, conformations can change dependent on aggregation state and solubility leading to significant uncertainty relating to interpretations of immunoreactivity with antibodies raised against Aβ. We review evidence relating to the reactivities of commonly used antibodies including 6F3D, 6E10 and 4G8 and evaluate their reactivity profiles with respect to AD diagnosis and research. Antibody cross-reactivities between Aβ-type, P3-type and Aβ-catabolic peptides confound interpretations of immunoreactivity. More than one antibody is required to adequately characterise Aβ. The relationships between anti-Aβ immunoreactivity, neuropathology and proposed APP cleavages are unclear. We find that the concept of Aβ lacks clarity as a specific entity. Anti-Aβ antibody cross-reactivities lead to significant uncertainty in our understanding of the APP proteolytic system and its role in AD with profound implications for current research and therapeutic strategies.
- 26 January 2017
- Published by Springer Nature in Journal of Negative Results in BioMedicine
- Vol. 16 (1) , 1-8
Open AccessDo anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?
Alzheimer disease (AD) research has focussed mainly on the amyloid beta protein (Aβ). However, many Aβ-and P3-type peptides derived from the amyloid precursor protein (APP) and peptides thought to derive from Aβ catabolism share sequence homology. Additionally, conformations can change dependent on aggregation state and solubility leading to significant uncertainty relating to interpretations of immunoreactivity with antibodies raised against Aβ. We review evidence relating to the reactivities of commonly used antibodies including 6F3D, 6E10 and 4G8 and evaluate their reactivity profiles with respect to AD diagnosis and research. Antibody cross-reactivities between Aβ-type, P3-type and Aβ-catabolic peptides confound interpretations of immunoreactivity. More than one antibody is required to adequately characterise Aβ. The relationships between anti-Aβ immunoreactivity, neuropathology and proposed APP cleavages are unclear. We find that the concept of Aβ lacks clarity as a specific entity. Anti-Aβ antibody cross-reactivities lead to significant uncertainty in our understanding of the APP proteolytic system and its role in AD with profound implications for current research and therapeutic strategies.
Solanezumab and the amyloid hypothesis for Alzheimer’s disease
Solanezumab’s failure is a wake-up call to look elsewhere for an answer to dementia Is the amyloid cascade hypothesis of Alzheimer’s disease too big to fail?1 It proposes that brain deposition of β amyloid protein is the critical early event in the pathogenesis of Alzheimer’s disease and has been the centrepiece of dementia research for decades.2 The hypothesis suggests that removing β amyloid will reverse or prevent the clinical expression of dementia. However, in all phase III clinical trials to date, treatments targeting β amyloid have failed to improve cognitive outcomes despite reducing brain β amyloid.3 It is widely argued that these negative trials do not disprove the hypothesis but that treatments should be given decades earlier before β amyloid has “caused” neuronal loss, or that the trials had included people without amyloid deposits.2 The results of a third trial investigating solanezumab (EXPEDITION3), a monoclonal antibody targeting amyloid plaques, were therefore eagerly awaited after the first two trials had negative results but with post hoc indications of potential effects on …
Solanezumab and the amyloid hypothesis for Alzheimer’s disease
Solanezumab’s failure is a wake-up call to look elsewhere for an answer to dementia Is the amyloid cascade hypothesis of Alzheimer’s disease too big to fail?1 It proposes that brain deposition of β amyloid protein is the critical early event in the pathogenesis of Alzheimer’s disease and has been the centrepiece of dementia research for decades.2 The hypothesis suggests that removing β amyloid will reverse or prevent the clinical expression of dementia. However, in all phase III clinical trials to date, treatments targeting β amyloid have failed to improve cognitive outcomes despite reducing brain β amyloid.3 It is widely argued that these negative trials do not disprove the hypothesis but that treatments should be given decades earlier before β amyloid has “caused” neuronal loss, or that the trials had included people without amyloid deposits.2 The results of a third trial investigating solanezumab (EXPEDITION3), a monoclonal antibody targeting amyloid plaques, were therefore eagerly awaited after the first two trials had negative results but with post hoc indications of potential effects on …